Medicus Pharma Ltd. (NASDAQ: MDCX) shares are surging 10.39% in pre-market trading Thursday, pushing the price to $0.17 from the previous regular close of $0.154. Volume has reached 4.5 million shares in the pre-market session, well above the stock's average daily volume of roughly 1.3 million shares.

Positive Phase 2 SkinJect Data Fueling Interest

The pre-market move follows last week's Phase 2 clinical data release for SkinJect, Medicus Pharma's non-invasive treatment for skin cancer. On September 10, the company published its abridged final Phase 2 clinical study report, identifying the 200 μg d-MNA patch as the lead development dose. That same day, Proactive Investors reported positive Phase 2 data for SkinJect in skin cancer treatment, with the company highlighting the patch's potential as a novel therapeutic approach.

The clinical results appear to be generating sustained investor interest, with trading activity continuing to elevated levels nearly a week after the initial data release.

Strategic Transformation Into Precision Oncology

The broader catalyst for renewed attention on MDCX appears tied to the company's strategic shift. On September 8, Medicus Pharma announced it was reorienting around a new cancer drug candidate and sharpening focus for other programs. The company formally announced its transformation into a precision oncology-led biotechnology company, moving beyond its original skin cancer focus to pursue a broader oncology strategy.

FDA Momentum on SkinJect Program

Beyond the recent data readouts, Medicus Pharma has been building momentum on its SkinJect program. In July, the company received FDA clearance to begin a registrational SkinJect study for Gorlin syndrome, a rare genetic condition that causes abnormal skin cell growth. The FDA issued a "Study May Proceed" letter, marking a key regulatory milestone toward potential approval.

Medicus Pharma has also advanced its Teverelix program, receiving positive FDA feedback and Central IRB approval for a Phase 2 study in acute urinary retention. The company appointed Dr. Faisal Mehmud as CEO of its UK subsidiary Antev Limited to lead that program.

What to Watch

Key things to monitor as regular trading begins:

  • Whether pre-market volume sustains into the regular session
  • Any additional Phase 2 data readouts or pipeline announcements
  • The company's next quarterly financial results
  • Progress on the SkinJect registrational study for Gorlin syndrome

Medicus Pharma currently has a market capitalization of approximately $3.75 million, with 22 million shares outstanding and a float of roughly 4.4 million shares. With only 12 employees and an early-stage pipeline, the stock carries significant clinical and regulatory risk.

Investors should note that penny-stock biotechs like MDCX experience heightened volatility, and moves driven by clinical data announcements can reverse just as quickly if subsequent results disappoint.